Table 3.
Characteristics of included studies on remdesivir. Abbreviations: CG: control group, IG: intervention group, IG1: intervention group 1, IG2: intervention group 2, IG3: intervention group 3, MV: mechanical ventilation [IQR]: interquartile range, No: number of patients, RCT: randomized controlled trial, SD: standard deviation, WHO: World Health Organization, ♂: male.
| Reference | Study Design/Population of Study | No. of Participants | Median Age, [IQR], Years | Sex ♂ |
|---|---|---|---|---|
| Remdesivir vs. Standard of care | ||||
| Spinner C., et al., 2020 [46] | RCT (open-label, phase III, multicentre)/Adults with moderate COVID-19 | IG1: n = 197 IG2: n = 199 CG: n = 200 | IG1: 56 [45–66] IG2: 58 [48–66] CG: 57 [45–66] |
IG1: 61% IG2: 60% CG: 63% |
| Remdesivir for 5 days vs. 10 days | ||||
| Goldman J., et al., 2020 [47] | RCT (open-label, phase III, multicentre)/Patients with severe COVID-19 | IG: n = 200; CG: n = 197 |
IG: 61 [50–69] CG: 62 [50–71] |
IG: 60% CG: 68% |
| Remdesivir vs. Placebo | ||||
| Beigel J., et al., 2020 [48] | RCT (double blind, multicentre, placebo-controlled)/Adults with moderate or severe COVID-19 |
IG: n = 541 CG: n = 521 |
Mean age, ± SD: IG: 58.6 ± 14.6 CG: 59.2 ± 15.4 |
IG: 65.1% CG: 63.7% |
| Remdesivir vs. Placebo | ||||
| Wang Y., et al., 2020 [49] | RCT (double blind, multicentre, placebo-controlled)/Adults with severe COVID-19 | IG: n = 158 CG: n = 78 |
IG: 66 [57–73] CG: 64 [53–70] |
IG: 56% CG: 65% |
| Remdesivir vs. Standard of care | ||||
| Pan et al., 2021 [50] | RCT (open-label, international, multicentre) WHO Solidarity trial consortium/Adults with COVID-19 |
IG: n = 2743 CG: n = 2708 |
Age 50–69 years: IG: 46.7% CG: 47.5% |
IG: 62.2% CG: 63.7% |
| Remdesivir vs. Standard of care | ||||
| Pasquini Z., et al., 2020 [51] | Observational and retrospective study/Critically ill patients under MV with confirmed COVID-19 and admitted to the intensive care unit | IG: n = 25 CG: n = 26 |
IG: 64 [57–75] CG: 70 [63.3–76] |
IG: 92% CG: 92.3% |
| Remdesivir vs. Standard of care | ||||
| Olender S., et al., 2020 [52] | IG: data from a phase III prospective, randomized RDV trial; CG: data from a longitudinal retrospective cohort/Adults with severe COVID-19 |
IG: n = 312 CG: n = 818 |
Age 40–64 years IG: 50% CG: 50% |
IG: 59% CG: 59% |
| Remdesivir vs. Supportive care | ||||
| Kalligeros M., et al., 2020 [53] | Observational, retrospective study/Adults with severe COVID-19 | GI: n = 99 GC: n = 125 |
IG: 58 [50–68] CG: 60 [50–68] |
IG: 69.7% CG: 64.8% |
| (Barticinib + Remdesivir) vs. Remdesivir | ||||
| Kalil P., et al., 2020 [54] | Double blind RCT (placebo-controlled)/Hospitalized adults with COVID-19 |
IG: n = 515 CG: n = 518 |
Mean age, ± SD: IG: 55 ± 15.4: CG: 55.8 ± 16 |
IG: 61.9% CG: 64.3% |